Selection of blockbuster announcements

1. Chow Tai Fook Jewellery released interim results, with a profit attributable to shareholders of HK $3.336 billion, down 6.84% from the same period last year.

$CHOW TAI FOOK (01929.HK)$Announcing results for the six months ended September 30, 2022, the Group's turnover increased by 5.32% to HK $46.535 billion in the first half of the financial year 2023. Profit attributable to shareholders fell 6.84 per cent to HK $3.336 billion, mainly due to a net foreign exchange loss of HK $0.33 per share due to a weaker renminbi. The board of directors declared an interim dividend of HK $0.22 per share. The dividend payout rate in the first half of fiscal year 2023 was about 66.0%.

2. Bosideng International announced interim results, and the profit attributable to equity shareholders increased by 15% to about 734 million yuan, or HK4.5 cents per share.

$BOSIDENG (03998.HK)$In the interim results for the six months ended September 30, 2022, revenue increased by 14.1% to about 6.18 billion yuan, operating profit increased by 0.6 percentage points to 15.3%, and profit attributable to the company's equity shareholders rose 15.0% year-on-year to about 734 million yuan. Basic earnings per share 6.79 cents, interim dividend per common share 4.5 Hong Kong cents.

3. Fuhong Hanlin signed a clinical trial R & D service agreement with real biology and Shanghai Fosun Pharmaceutical industrial development.

$HENLIUS-B (02696.HK)$According to the announcement, on November 24, 2022, the company entered into a clinical trial R & D service agreement with Real Biology and Shanghai Fosun Pharmaceutical Industrial Development. The company agreed to provide clinical trial R & D services related to Azvudine and Shanghai Fosun Pharmaceutical prevention, including clinical project design and management services, to Real Biology and novel coronavirus Industrial Development.

4. The first patient implanted in the world's first human clinical trial of Peijia Medical-B:MonarQ transcatheter tricuspid valve replacement system.

$Peijia Medical Limited (09996.HK)$In an announcement, the company successfully completed the first patient implantation in the world's first human (FIM) clinical trial of the MonarQ transcatheter tricuspid valve replacement (TTVR) system in cooperation with inQB8 Medical Technologies, LLC (inQB8).

The MonarQ TTVR system is an innovative technology choice for the treatment of tricuspid regurgitation. The system has a unique biodynamic attachment system, which can use and maintain the natural movement of the heart, fix the implant on the primary lobule and disperse the contractile load of the heart. widely adapt to the size of the primary annulus and reduce the occurrence of perivalvular leakage as much as possible.

Tencent (00700) invested about HK $350 million to buy back 1.24 million shares on November 24th.

$TENCENT (00700.HK)$It issued an announcement to repurchase 1.24 million shares at a repurchase price of HK $279-HK $289.2 per share at a cost of about HK $350 million on November 24, 2022.

Important matters

United (00486) has transferred the interim dividend to the Hong Kong share registrar

China Southern Airlines (01055) completed a non-public offering of 804 million A-shares with a net raise of 4.496 billion yuan

Total contract sales of Shenzhen Holdings (00604) from January to October are about 9.828 billion yuan.

Financial data

Bosideng International (03998) announced interim results profit attributable to equity shareholders increased by 15% to about 734 million HKD per share.

Chow Tai Fook Jewellery (01929) announced interim results: net profit fell 6.8% to HK $3.336 billion, with an interim dividend of HK $0.22 per share.

Investment and operation

China Software International (00354): using the whole stack independent controllable technology to sign a contract with the Department of Human Society of Henan Province to build a digital security system of social security fund.

Peijia Medical-B (09996): first patient implantation in the world's first human clinical trial of MonarQ transcatheter tricuspid valve replacement system

Haichang Ocean Park (02255) signed a cooperation framework agreement with Dalian Forest Zoo to jointly create an international IP theme entertainment project of Dalian Forest Zoo.

China Evergrande Group (03333): put forward administrative reconsideration on the free resumption of 11 plots of land in Wuhan.

China Merchants Land (00978) intends to sell 51% equity in Kaida City, Foshan City for 408 million yuan.

China Huarong (02799) completes the full circulation of a number of domestic shares and resumes public ownership

Quanfeng Holdings (02285) participates in the A-share increase of Quanfeng Automobile with 358 million yuan

Increase and decrease holdings

Industrial and Commercial Bank of China (01398) was awarded 83 million shares by China Taiping Insurance Group.

Guangzhou Automobile Group (02238) was reduced by 3.2469 million shares by JPMorgan Chase & Co

Cosco Seaport (01199) gained 6.338 million shares by COSCO Shipping Holdings

CANSINOBIO (06185) was awarded 582700 shares by JPMorgan Chase & Co

Repurchase cancellation

Tencent (00700) spent HK $350 million to buy back 1.24 million shares on November 24th

AIA Group Limited (01299) spent HK $225 million to buy back 3.0034 million shares on November 24th

China Petroleum & Chemical Corporation (00386) spent HK $79.5157 million to buy back 22.534 million shares on November 24th

Haier Smart Home (06690) spent HK $19.5836 million to buy back 800000 shares on November 24th

Swire AG A (00019) spent HK $14.8867 million to buy back 248500 shares on November 24th

Equity incentive

XIAOMI Group-W (01810) granted a total of 43.3206 million award shares

Aluminum Corporation Of China Ltd (02600): awarding 27.5363 million restricted shares to 285 motivators

San Nuo Pharmaceuticals-B (02257) granted a total of 1.51 million share options and 903000 restricted shares